Heartflow is preparing to list on the Nasdaq aiming to raise more than $208 million by offering shares priced between $15 and $17. The company, utilizing AI in its technology, has developed personalized 3D models of patients' hearts to diagnose cardiac and coronary diseases, recently receiving FDA approval. As of March 2025, Heartflow has assessed over 400,000 patients. Despite growing revenue of $125.8 million in 2024, the company posted a net loss of $96.4 million last year.
Heartflow, a California-based medtech company, is set to list shares on the Nasdaq, aiming to raise over $208 million by offering 12.5 million shares.
Utilizing AI, Heartflow creates personalized 3D models of patients' hearts to evaluate coronary and cardiac issues, gaining FDA approval and expanding Medicare coverage.
Heartflow generated $125.8 million in revenue in 2024, marking a 44% increase from the previous year, although the company reported a net loss of $96.4 million.
Collection
[
|
...
]